40240-12-8

Basic information

• Product Name: N-Benzyl-1,2,3,6-tetrahydropyridine
• Synonyms: N-Benzyl-1,2,3,6-tetrahydropyridine;1-Benzyl-1,2,3,6-tetrahyd...;1-(Phenylmethyl)-1,2,3,6-tetrahydropyridine
• CAS NO: 40240-12-8
• Molecular Formula: C₁₂H₁₅N
• Molecular Weight: 173.258
• Mol File: 40240-12-8.mol
• Article Data: 44

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 99℃
• Appearance: /
• Density: 1.024
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.09±0.20(Predicted)
• CAS DataBase Reference: N-Benzyl-1,2,3,6-tetrahydropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: N-Benzyl-1,2,3,6-tetrahydropyridine(40240-12-8)
• EPA Substance Registry System: N-Benzyl-1,2,3,6-tetrahydropyridine(40240-12-8)

Safety Data

• Hazardous Substances Data: 40240-12-8(Hazardous Substances Data)

Usage

General Description

N-Benzyl-1,2,3,6-tetrahydropyridine, also known as MPTP, is a chemical compound that has been used in scientific research to study Parkinson's disease. MPTP is converted into a toxic compound called MPP+ in the body, which damages the cells in the substantia nigra region of the brain, leading to symptoms similar to Parkinson's disease. It has been used to create animal models of Parkinson's disease in research studies. MPTP is considered a neurotoxin and poses a significant risk to human health if not handled properly. It is important to take appropriate safety precautions when working with MPTP in laboratory settings.

InChI:InChI=1S/C12H15N/c1-3-7-12(8-4-1)11-13-9-5-2-6-10-13/h1-5,7-8H,6,9-11H2

Upstream product

• 694-05-3 1,2,3,6-tetrahydropyridine 
• 100-52-7 benzaldehyde 
• 50-00-0 formaldehyd 
• 109154-23-6 3,3-bis(trimethylsilyl)prop-1-ene 
• 100-46-9 benzylamine 
• 67686-01-5 1-benzyl-4-piperidinemethanol 
• 110-86-1 pyridine 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 
• 41780-52-3 N’-(1-benzylpiperidin-4-ylidene)-4-methylbenzenesulfonohydrazide 
• 90892-59-4 1-(1-methylphenyl)piperidin-4-yl methanesulfonate 
• 280-64-8 9-bora-bicyclo[3.3.1]nonane 
• 53234-67-6 4-(1-phenylmethyl-1,2,5,6-tetrahydro-4-pyridyl)morpholine 
• 98-88-4 benzoyl chloride 

Downstream Products

• 694-05-3 1,2,3,6-tetrahydropyridine 
• 63588-62-5 1-benzyl-3,4-dibromo-piperidine 
• 725715-12-8 3-(phenylmethyl)-7-oxa-3-azabicyclo[4.1.0]heptane 
• 66207-23-6 1-benzyloxycarbonyl-1,2,3,6-tetrahydropyridine 
• 1062601-62-0 (-)-(3R,4S)-1-benzyl-3,4-epoxypiperidine 
• 1384733-04-3 C₁₀H₁₀O₄*C₁₉H₂₄N₂O 
• 1384733-07-6 C₁₂H₁₅NO 
• 91564-35-1 C₁₂H₁₇NO₂ 
• 1510832-47-9 C₂₄H₃₅ClF₃N₃O₅ 

Relevant articles and documents

Trans-3-Hydroxy-4-morpholinopiperidine - The pH-triggered conformational switch with a double flip

Derivatives of trans-3-hydroxy-4-aminopiperidine are suggested as potential pH-sensitive conformational switches able to perform two consecutive flips (or flip-flop) when basicity/acidity of solution changes. Such a double switch of conformation was detected by 1H NMR for a model compound - trans-3-hydroxy-4-morpholinopiperidine. A combination of hydrogen bonding and electrostatic/dipole-dipole interactions was suggested for rationalization. Computational studies provided additional insight into the complex intra- and intermolecular forces that determine the relative stabilities of conformers. In similar structures an incorporated trans-3-hydroxy-4-aminopiperidine moiety can serve as a conformational pH-trigger when equipped with substituents designed to perform certain geometry-dependent functions, for example, as cation chelators or as lipid tails.

-

The 3,3-bis(trimethylsilyl)propene reacts with iminium ions (generated in situ from primary amines) by an aminomethylation-desilylation process and a subsequent cyclization, leading to N-alkyl-1,2,3,6-tetrahydropyridines as principal products. Tetrahydro-1,3-oxazines with a bis(trimethylsilyl)methyl group may also be observed. When primary amines with a tertiary group are used, the reaction leads only to ω-aminovinylsilanes, the steric hindrance inhibiting the progression of the reaction.

PRMT5 INHIBITORS

The present invention provides a compound selected from: compounds A, B, C, D and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds disclosed herein, pharmaceutic

ENANTIOMERIC COMPOUNDS

The present invention relates to enantiomeric compounds, their use in stereospecific reactions and to a method of preparing enantiomeric compounds.

Normal Alpha Olefin Synthesis Using Dehydroformylation or Dehydroxymethylation

The present invention discloses processes for producing normal alpha olefins, such as 1-hexene, 1-octene, 1-decene, and 1-dodecene in a multistep synthesis scheme from another normal alpha olefin. Also disclosed are reactions for converting aldehydes, primary alcohols, and terminal vicinal diols into normal alpha olefins.